Table 2 Summary of progression-free survival analysis (bone only metastasis patients excluded).
Parameters | No. | Event | Median survival | Log-rank | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|---|---|
(95%CI) | P value | HR(95%CI) | P value | HR(95%CI) | P value | |||
No. of metastatic sites | ||||||||
1 | 3 | 2 | 19.6 (Not reached) | 0.65 | 1.1 (0.6–2.2) | 0.66 | ||
2 | 10 | 7 | 6.3 (0.0–14.0) | |||||
≥3 | 14 | 7 | 6.5 (0.0–13.8) | |||||
Liver metastasis | ||||||||
Yes | 6 | 5 | 3.0 (1.1–4.9) | 0.001 | 8.9 (2.1–38.7) | 0.004* | 5.6 (1.1–27.0) | 0.017* |
No | 21 | 11 | 11.9 (1.2–22.6) | |||||
Line of endocrine therapy for MBC | ||||||||
1 | 19 | 10 | 16.6 (5.8–27.6) | 0.019 | 3.8 (1.1–12.9) | 0.029* | ||
≥2 | 8 | 6 | 3.3 (2.1–4.4) | |||||
Prior palliative chemotherapy | ||||||||
Yes | 8 | 4 | 6.5 (0–15.7) | 0.95 | 0.97 (0.3–3.0) | 0.95 | ||
No | 19 | 12 | 9.4 (3.1–15.7) | |||||
COV | ||||||||
<0.275 | 14 | 8 | 8.6 (0.3–16.9) | 0.55 | 0.7 (0.3–2.0) | 0.55 | ||
≥0.275 | 13 | 8 | 9.4 (2.4–16.4) | |||||
HI | ||||||||
<2.05 | 13 | 9 | 5.6 (0.45–10.7) | 0.027 | 0.26 (0.07–0.9) | 0.036* | 0.69 (0.13–0.94) | 0.043* |
≥2.05 | 14 | 7 | 16.7 (8.6–24.7) | |||||
SUVmax | ||||||||
<6.09 | 14 | 10 | 5.6 (1.3–9.9) | 0.026 | 0.32 (0.1–0.91) | 0.033* | 0.50 (0.15–0.84) | 0.025* |
≥6.09 | 13 | 6 | 17.3 (11.4–23.9) | |||||
SUVmean | ||||||||
<3.92 | 13 | 9 | 5.6 (1.7–9.4) | 0.189 | 0.51 (0.18–1.4) | 0.19 | ||
≥3.92 | 14 | 7 | 16.7 (7.2–26.1) | |||||
MTV(ml) | ||||||||
<18.78 | 13 | 8 | 6.3 (0–14.5) | 0.438 | 0.67 (0.24–1.8) | 0.44 | ||
≥18.78 | 14 | 8 | 16.7 (3.8–29.6) | |||||
TLG(g) | ||||||||
<72.5 | 13 | 8 | 6.3 (0–13.6) | 0.419 | 0.66 (0.24–1.8) | 0.42 | ||
≥72.5 | 14 | 8 | 16.7 (3.8–29.6) | |||||
